770 related articles for article (PubMed ID: 33306195)
1. Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis.
Solorzano-Ibarra F; Alejandre-Gonzalez AG; Ortiz-Lazareno PC; Bastidas-Ramirez BE; Zepeda-Moreno A; Tellez-Bañuelos MC; Banu N; Carrillo-Garibaldi OJ; Chavira-Alvarado A; Bueno-Topete MR; Del Toro-Arreola S; Haramati J
Clin Exp Immunol; 2021 Apr; 204(1):78-95. PubMed ID: 33306195
[TBL] [Abstract][Full Text] [Related]
2. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V
World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406
[TBL] [Abstract][Full Text] [Related]
3. Early transient suppression of immune checkpoint proteins T-cell immunoglobulin mucin-3 and programmed cell death-1 in peripheral blood lymphocytes after blastocyst transfer is associated with successful implantation.
Zhang T; Zhu W; Zhao Y; Cheung WC; Liu Y; Chen X; Du Y; Leung KT; Chan YL; Wang CC; Laird S; Li TC
Fertil Steril; 2020 Aug; 114(2):426-435. PubMed ID: 32199622
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint markers and anti-CD20-mediated NK cell activation.
Wang Z; Weiner GJ
J Leukoc Biol; 2021 Oct; 110(4):723-733. PubMed ID: 33615552
[TBL] [Abstract][Full Text] [Related]
5. Immune phenotype of patients with stage IV metastatic inflammatory breast cancer.
Fernandez SV; MacFarlane AW; Jillab M; Arisi MF; Yearley J; Annamalai L; Gong Y; Cai KQ; Alpaugh RK; Cristofanilli M; Campbell KS
Breast Cancer Res; 2020 Dec; 22(1):134. PubMed ID: 33267869
[TBL] [Abstract][Full Text] [Related]
6. Selective downregulation of natural killer activating receptors on NK cells and upregulation of PD-1 expression on T cells in children with severe and/or recurrent Herpes simplex virus infections.
Lenart M; Kluczewska A; Szaflarska A; Rutkowska-Zapała M; Wąsik M; Ziemiańska-Pięta A; Kobylarz K; Pituch-Noworolska A; Siedlar M
Immunobiology; 2021 May; 226(3):152097. PubMed ID: 34015527
[TBL] [Abstract][Full Text] [Related]
7. Direct-acting antiviral treatment downregulates immune checkpoint inhibitor expression in patients with chronic hepatitis C.
Szereday L; Meggyes M; Berki T; Miseta A; Farkas N; Gervain J; Par A; Par G
Clin Exp Med; 2020 May; 20(2):219-230. PubMed ID: 32108916
[TBL] [Abstract][Full Text] [Related]
8. Development of Anti-human T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT) Monoclonal Antibodies for Flow Cytometry.
Takei J; Asano T; Nanamiya R; Nakamura T; Yanaka M; Hosono H; Tanaka T; Sano M; Kaneko MK; Harada H; Kato Y
Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):71-75. PubMed ID: 33900817
[TBL] [Abstract][Full Text] [Related]
9. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ
J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173
[TBL] [Abstract][Full Text] [Related]
10. Serial changes in two immune checkpoint receptors and ligands, Tim-3/Gal-9 and PD-1/PD-L1 in peripheral blood prior to miscarriage: Comparison with pregnancies resulting in a live birth.
Zhang T; Zhao Y; Cheung WC; Gan YH; Huang L; Li M; Leung KT; Chung PW; Wang CC; Laird S; Chen X; Li TC
Am J Reprod Immunol; 2022 May; 87(5):e13524. PubMed ID: 35130363
[TBL] [Abstract][Full Text] [Related]
11. LIGHT (TNFSF14) Costimulation Enhances Myeloid Cell Activation and Antitumor Immunity in the Setting of PD-1/PD-L1 and TIGIT Checkpoint Blockade.
Yoo KJ; Johannes K; González LE; Patel A; Shuptrine CW; Opheim Z; Lenz K; Campbell K; Nguyen TA; Miriyala J; Smith C; McGuire A; Tsai YH; Rangwala F; de Silva S; Schreiber TH; Fromm G
J Immunol; 2022 Aug; 209(3):510-525. PubMed ID: 35817517
[TBL] [Abstract][Full Text] [Related]
12. Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile.
Krijgsman D; de Vries NL; Skovbo A; Andersen MN; Swets M; Bastiaannet E; Vahrmeijer AL; van de Velde CJH; Heemskerk MHM; Hokland M; Kuppen PJK
Cancer Immunol Immunother; 2019 Jun; 68(6):1011-1024. PubMed ID: 31053876
[TBL] [Abstract][Full Text] [Related]
13. Human peripheral blood DNAM-1
Stannard KA; Lemoine S; Waterhouse NJ; Vari F; Chatenoud L; Gandhi MK; Martinet L; Smyth MJ; Guillerey C
Blood Adv; 2019 Jun; 3(11):1681-1694. PubMed ID: 31167820
[TBL] [Abstract][Full Text] [Related]
14. PD-1, CTLA-4, LAG-3, and TIGIT: The roles of immune checkpoint receptors on the regulation of human NK cell phenotype and functions.
Esen F; Deniz G; Aktas EC
Immunol Lett; 2021 Dec; 240():15-23. PubMed ID: 34599946
[TBL] [Abstract][Full Text] [Related]
15. Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions.
Arreygue-Garcia NA; Daneri-Navarro A; del Toro-Arreola A; Cid-Arregui A; Gonzalez-Ramella O; Jave-Suarez LF; Aguilar-Lemarroy A; Troyo-Sanroman R; Bravo-Cuellar A; Delgado-Rizo V; Garcia-Iglesias T; Hernandez-Flores G; Del Toro-Arreola S
BMC Cancer; 2008 Jan; 8():16. PubMed ID: 18208618
[TBL] [Abstract][Full Text] [Related]
16. Looking past PD-L1: expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia.
Curley J; Conaway MR; Chinn Z; Duska L; Stoler M; Mills AM
Mod Pathol; 2020 Jun; 33(6):1182-1192. PubMed ID: 32139873
[TBL] [Abstract][Full Text] [Related]
17. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
18. High CD56++CD16- natural killer (NK) cells among suboptimal immune responders after four years of suppressive antiretroviral therapy in an African adult HIV treatment cohort.
Bayigga L; Nabatanzi R; Sekiziyivu PN; Mayanja-Kizza H; Kamya MR; Kambugu A; Olobo J; Kiragga A; Kirimunda S; Joloba M; Nakanjako D
BMC Immunol; 2014 Jan; 15():2. PubMed ID: 24483185
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of TIGIT and KLRG1 correlates with impaired CD56
Nie Y; Liu D; Yang W; Li Y; Zhang L; Cheng X; Chen R; Yuan B; Zhang G; Wang H
Virol J; 2022 Apr; 19(1):68. PubMed ID: 35413989
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation.
Roberts A; Bentley L; Tang T; Stewart F; Pallini C; Juvvanapudi J; Wallace GR; Cooper AJ; Scott A; Thickett D; Lugg ST; Bancroft H; Hemming B; Ferris C; Langman G; Robinson A; Chapman J; Naidu B; Pinkney T; Taylor GS; Brock K; Stamataki Z; Brady CA; Curnow SJ; Gordon J; Qureshi O; Barnes NM
Sci Rep; 2021 Feb; 11(1):4030. PubMed ID: 33597595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
